Prognostic significance of vascular endothelial growth factor and its receptors in endometrial carcinoma.

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Gynecologic Oncology

• Publication date

  2000-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1006/GYNO.2000.5802PMID 10831352
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Tumor angiogenesis

  2020cited by this paper
• Vascular endothelial growth factor-C expression in human prostatic carcinoma and its relationship to lymph node metastasis

  1999cited by this paper
• Angiogenesis of the endometrium.

  1999cited by this paper
• VEGF, VEGFR‐1, VEGFR‐2, microvessel density and endothelial cell proliferation in tumours of the ovary

  1999cited by this paper
• Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate.

  1998cited by this paper
• Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4).

  1998cited by this paper
• Validation of anti‐vascular endothelial growth factor (anti‐VEGF) antibodies for immunohistochemical localization of VEGF in tissue sections: expression of VEGF in the human endometrium

  1998cited by this paper
• Value of glutathione S-transferase pi and the oncogene products c-Jun, c-Fos, c-H-Ras, and c-Myc as a prognostic indicator in endometrial carcinomas.

  1998cited by this paper
• Association of vascular endothelial growth factor expression with tumor cell proliferation in ovarian carcinoma.

  1997cited by this paper
• Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: correlation with clinicopathology and patient survival, and analysis of serum VEGF levels.

  1997cited by this paper
• Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma.

  1997cited by this paper
• Indispensability of pelvic and paraaortic lymphadenectomy in endometrial cancers.

  1997cited by this paper
• Vessel counts and expression of vascular endothelial growth factor as prognostic factors in node-negative colon cancer.

  1997cited by this paper
• Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenes

  1997cited by this paper
• Expression and localization of the vascular endothelial growth factor family in ovarian epithelial tumors.

  1997cited by this paper
• Immunohistochemical study of tumour angiogenesis in oral squamous cell carcinoma.

  1997cited by this paper
• The biology of vascular endothelial growth factor.

  1997cited by this paper
• Vascular endothelial growth factor expression in early stage ovarian carcinoma

  1997cited by this paper
• Prognostic value of vascular endothelial growth factor and its receptor Flt‐1 in squamous cell lung cancer

  1997cited by this paper
• A novel vascular endothelial growth factor, VEGF‐C, is a ligand for the Flt4 (VEGFR‐3) and KDR (VEGFR‐2) receptor tyrosine kinases.

  1996cited by this paper
• Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in endometrial carcinoma

  1996cited by this paper
• Prognostic value of vascular endothelial growth factor expression in gastric carcinoma

  1996cited by this paper
• Strong expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in ovarian borderline and malignant neoplasms.

  1996cited by this paper
• Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer.

  1995cited by this paper
• Colocalisation of vascular endothelial growth factor and its Flt-1 receptor in human placenta.

  1995cited by this paper
• Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development.

  1995cited by this paper
• Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma.

  1995cited by this paper
• Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis.

  1995cited by this paper
• Association of Vascular Endothelial Growth Factor Expression with Tumor Angiogenesis and with Early Relapse in Primary Breast Cancer

  1994cited by this paper
• VEGF/VPF: the angiogenesis factor found?

  1993cited by this paper
• Tumor angiogenesis: review of current applications in tumor prognostication.

  1993cited by this paper
• FLT4 receptor tyrosine kinase contains seven immunoglobulin-like loops and is expressed in multiple human tissues and cell lines.

  1992cited by this paper

• Expression of Vegf in Endometrial Hyperplasia with and Without Atypia And Endometrioid Endometrial Carcinoma and Its Association With Clinicopathological Parameters.

  2024cites this paper
• The prognostic value of vascular endothelial growth factor in endometrial cancer: A protocol for systematic review and meta-analysis

  2024cites this paper
• Hypermethylation of the sodium channel beta subunit gene promoter is associated with colorectal cancer

  2024cites this paper
• Expression analysis of TRAF2‑ and NCK‑interacting protein kinase (TNIK) and phosphorylated TNIK in papillary thyroid carcinoma

  2023cites this paper
• Angiogenesis in gynecological cancers and the options for anti-angiogenesis therapy.

  2020cites this paper
• Can VEGFR-3 be a better tumor marker for breast cancer than CA 15-3?

  2020cites this paper
• Study of ER, PR and VEGF Expression in Endometrial Epithelial Neoplasms and its Correlation with Histological Stage and Grade of Endometrial Carcinoma

  2020cites this paper
• Prognostic significance of VEGF and components of the plasminogen activator system in endometrial cancer

  2020cites this paper
• CT textural analysis of gastric cancer: correlations with immunohistochemical biomarkers

  2018cites this paper
• Biomarker potential of IL-6 and VEGF-A in ascitic fluid of epithelial ovarian cancer patients.

  2018cites this paper
• The role of bevacizumab on tumour angiogenesis and in the management of gynaecological cancers: A review.

  2018cites this paper
• Clinical significance of pretreatment serum levels of VEGF and its receptors, IL- 8, and their prognostic value in type I and II endometrial cancer patients

  2017cites this paper
• Targeting angiogenesis in endometrial cancer - new agents for tailored treatments

  2016cites this paper
• Management of Advanced Endometrial Cancer and Inhibitors of the PI3K/AKT/mTOR Pathway

  2015cites this paper
• Oncostatin M activates STAT3 to promote endometrial cancer invasion and angiogenesis.

  2015cites this paper
• Endoglin, VEGF, and its receptors in predicting metastases in endometrial carcinoma

  2014cites this paper
• A phase II evaluation of pazopanib in the treatment of recurrent or persistent carcinosarcoma of the uterus: a gynecologic oncology group study.

  2014cites this paper
• A phase II trial of sunitinib in women with metastatic or recurrent endometrial carcinoma: a study of the Princess Margaret, Chicago and California Consortia.

  2014cites this paper
• SHARP1 Suppresses Angiogenesis of Endometrial Cancer by Decreasing Hypoxia-Inducible Factor-1α Level

  2014cites this paper
• Pretreatment serum levels of bFGF and VEGF and its clinical significance in endometrial carcinoma.

  2013cites this paper
• Preoperative assessment of endometrial carcinoma

  2013cites this paper
• Prognostic value of tgfb1 protein in endometrioid adenocarcinoma

  2013cites this paper
• Medical Therapy of Endometrial Cancer

  2012cites this paper
• Relationship between expression and prognostic ability of PTEN, STAT3 and VEGF-C in colorectal cancer

  2012cites this paper
• Bevacizumab in endometrial cancer treatment

  2012cites this paper
• Serum levels of VEGF and VEGF-C in patients with endometrial cancer.

  2011cites this paper
• Tissue and serum biomarkers as prognostic variables in endometrioid-type endometrial cancer.

  2011cites this paper
• Promising novel therapies for the treatment of endometrial cancer.

  2010cites this paper
• Expression of vascular endothelial growth factor (VEGF) and assessment of microvascular density with CD34 as prognostic markers for endometrial carcinoma.

  2010cites this paper
• Vascular endothelial growth factor and intratumoral microvessel density as prognostic factors in endometrial cancer.

  2010cites this paper
• Assessment of sVEGFR-1 concentration in patients with breast cancer

  2010cites this paper
• Body Mass and the Risk of Endometrial Cancer

  2010cites this paper
• Current challenges in clinical management of endometrial cancer.

  2009cites this paper
• Biologic markers in endometrial cancer treatment

  2009cites this paper
• Immunohistochemical Markers in Endometrial Hyperplasia: Is There a Panel With Promise?: A Review

  2008cites this paper
• The Determination of VEGF and MVD, among Patients with Primary Breast Cancer

  2008cites this paper
• A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group study.

  2007cites this paper
• The ratio of membrane-bound form Flt-1 mRNA to VEGF mRNA correlates with tumor angiogenesis and prognosis in non-small cell lung cancer.

  2007cites this paper
• The Potential Role of Intrinsic Hypoxia Markers as Prognostic Variables in Cancer

  2007cites this paper
• Expression of vascular endothelial growth factor and assessment of microvascular density with CD 34 and endoglin in proliferative endometrium, endometrial hyperplasia, and endometrial carcinoma

  2007cites this paper
• Biochemical markers in oncology. Part I: molecular basis. Part II: clinical uses.

  2007cites this paper
• Bevacizumab therapy in patients with recurrent uterine neoplasms.

  2007cites this paper
• A phase II trial of thalidomide in patients with refractory leiomyosarcoma of the uterus and correlation with biomarkers of angiogenesis: a gynecologic oncology group study.

  2007cites this paper
• Hormone therapy in advanced and recurrent endometrial cancer: a systematic review

  2006cites this paper
• CD105 expression is an independent predictor of survival in patients with endometrial cancer.

  2006cites this paper
• Morphology of angiogenesis in human cancer: a conceptual overview, histoprognostic perspective and significance of neoangiogenesis

  2005cites this paper
• VEGF and Its Receptors (flt-1 and KDR/flk-1) as Prognostic Indicators in Endometrial Carcinoma

  2005cites this paper
• Lymphangiogenesis in human gynaecological cancers

  2005cites this paper
• Prediction of metastasis risk (11 year follow-up) using VEGF-R1, VEGF-R2, Tie-2/Tek and CD105 expression in breast cancer (n=905)

  2004influential citation
• Angiogenic factors and the endometrium following long term progestin only contraception.

  2004cites this paper
• Endometrial Angiogenesis: From Physiology to Pathology

  2004cites this paper
• Gene expression profiling of oral squamous cell carcinoma using laser microdissection and cDNA microarray

  2004cites this paper
• Lymphangiogenesis and tumor metastasis

  2003cites this paper
• Lymphangiogenesis and tumor metastasis

  2003cites this paper
• A case of adenocarcinoma of the endometrial type mixed with a clear cell component that metastasized to the vagina.

  2003cites this paper
• [Prognostic significance of VEGF receptors, VEGFR-1 (Flt-1) and VEGFR-2 (KDR/Flk-1) in breast carcinoma].

  2003cites this paper
• Endoglin (CD105) Expression in Endometrial Carcinoma

  2003cites this paper
• Vascular endothelial growth factor-D is an independent prognostic factor in epithelial ovarian carcinoma

  2003cites this paper
• Correspondence re: S. Maula et al., intratumoral lymphatics are essential for the metastatic spread and prognosis in squamous cell carcinoma of the head and neck. Cancer Res., 63: 1920-1926, 2003.

  2003cites this paper
• Role of Growth Factors in Tumor Growth and Progression of Gynecological Tumors

  2003cites this paper
• Prevention and treatment of lymphatic metastasis by antilymphangiogenic therapy.

  2002cites this paper
• Current status and future innovations of hormonal agents, chemotherapy and investigational agents in endometrial cancer

  2002cites this paper
• Carbonyl reductase as a significant predictor of survival and lymph node metastasis in epithelial ovarian cancer

  2001cites this paper
• High sensitivity of PCR in situ hybridization for the detection of human papillomavirus infection in uterine cervical neoplasias.

  2001cites this paper
• Immunohistochemical analysis of gynecologic tumors.

  2001cites this paper
• Novel strategies for systemic treatment of endometrial cancer

  2000cites this paper